Show simple item record

dc.contributor.authorBalbach, Melanie
dc.contributor.authorFushimi, Makoto
dc.contributor.authorHuggins, David
dc.contributor.authorSteegborn, Clemens
dc.contributor.authorMeinke, Peter
dc.contributor.authorLevin, Lonny
dc.contributor.authorBuck, Jochen
dc.date.accessioned2020-05-14T14:13:04Z
dc.date.available2020-05-14T14:13:04Z
dc.date.issued2020-04
dc.identifier.urihttps://hdl.handle.net/1813/69929
dc.description.abstractEfforts to develop new male or female non-hormonal, orally available contraceptives assume that to be effective and safe, targets must be (1) essential for fertility; (2) amenable to targeting by small-molecule inhibitors; and (3) restricted to the germline. In this perspective, we question the third assumption and propose that despite its wide expression, soluble adenylyl cyclase (sAC: ADCY10), which is essential for male fertility, is a valid target. We hypothesize that an acute-acting sAC inhibitor may provide orally available, on-demand, non-hormonal contraception for men without adverse, mechanism-based effects. To test this concept, we describe a collaboration between academia and the unique capabilities of a public-private drug discovery instituteen_US
dc.language.isoen_USen_US
dc.publisherOxford Academicen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcontraceptivesen_US
dc.subjectdrug discoveryen_US
dc.titleOptimization of lead compounds into on-demand, non-hormonal contraceptives: leveraging a public-private drug discovery institute collaborationen_US
dc.typearticleen_US
dc.relation.doihttps://doi.org/10.1093/biolre/ioaa052en_US
dc.identifier.pmid32307523


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

Statistics